EIP Pharma Inc., of Cambridge, Mass., said it completed a new private funding round of $11.2 million to support the use of the investigational drug neflamapimod as a treatment for dementia with Lewy bodies and for the cognitive deficits in Huntington's disease. Phase II studies in those indications are expected to start in the second quarter.